Syncom Formulations Q1 profit jumps 58% to Rs 24.85 crore

Syncom Formulations (India) Ltd reported a 58 per cent rise in consolidated profit after tax to Rs 24.85 crore for the June quarter, compared with Rs 15.75 crore a year earlier, driven by an ethical prescription-led business model. Total income grew 8 per cent to Rs 133.36 crore from Rs 122.94 crore in the same period last year, the company said in a regulatory filing.

Profit before tax rose 59 per cent to Rs 32.25 crore, while revenue from operations increased nearly 7 per cent to Rs 125.53 crore. Earnings per share improved to Rs 0.26 from Rs 0.17. The board recommended a final dividend of Rs 0.10 per equity share for the 2025-26 financial year, subject to shareholder approval at the annual general meeting.

Chairman Ankit Kedarmal Bankda attributed the performance to quality manufacturing and long-term trust with the medical community. The company, which exports to over 15 countries, operates six divisions and a field force of over 1,000 medical representatives. Its women's healthcare brands Ovafresh and Ovafresh-M are among the leading national names in the IVF and gynaecology segment.